Symplicity Spyral Renal Denervation Catheter
Medtronic, Inc. · Decision date Mar 25, 2026
What did the FDA decide?
FDA records P220026/S016 as a supplement to PMA P220026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 25, 2026.
An approval order statement is not included in the imported record. Open the FDA listing for the decision documents.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 25, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220026/S016
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- Decision code
- OK30
- Decision date
- Mar 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ablation catheter, renal denervation.
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220026 · Original PMA
Symplicity Spyral Renal Denervation System
P220026/S016 received
Application receipt date recorded by FDA.
P220026/S015 · Related supplement
Symplicity Spyral Multi-Electrode Renal Denervation Catheter
P220026/S016 · FDA decision
30-Day Notice
P220026/S017 · Related supplement
Symplicity Spyral Renal Denervation System
P220026/S014 · Related supplement
Symplicity Spyral Renal Denervation System
P220026/S019 · Related supplement
Symplicity G3 Renal Denervation RF Generator
Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Nov 17, 2023 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 27, 2026 | FDA | |
Symplicity Spyral Renal Denervation SystemP220026/S017 | Medtronic, Inc. | PMA supplement | Jul 16, 2026 | FDA |
Symplicity Spyral Renal Denervation SystemP220026/S014 | Medtronic, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Symplicity G3 Renal Denervation RF GeneratorP220026/S019 | Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code QYI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Recor Medical, Inc. | PMA supplement | Aug 13, 2026 | FDA | |
| Recor Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
ReCor Paradise CatheterP220023/S009 | Recor Medical, Inc. | PMA supplement | Sep 11, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220026/S016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



